Design, synthesis, biological evaluation, and molecular modeling of coumarin-piperazine derivatives as acetylcholinesterase inhibitors

Arch Pharm (Weinheim). 2013 Nov;346(11):793-804. doi: 10.1002/ardp.201300242. Epub 2013 Oct 8.

Abstract

Acetylcholinesterase (AChE) is an important drug target for the treatment of Alzheimer's disease. A novel series of coumarin-piperazine derivatives were synthesized and their potency to inhibit human AChE enzyme (hAChE) was studied. All the final compounds were characterized by infrared, (1)H NMR, (13)C NMR, and elemental analysis. Docking experiments of the designed coumarin-piperazine derivatives were carried out in order to compare the theoretical and experimental binding affinities toward hAChE, to delineate the inhibitory mechanism. Subsequently, a structure-activity relationship (SAR) study using the molecular field method showed that the hydrophobic field and positive charge center conferred by the coumarin and piperazine moieties demonstrated an inhibitory mechanism. Among the compounds tested, 3f, 3j, and 3m were found to be the most potent inhibitors of hAChE.

Keywords: Alzheimer's disease; Coumarin; Docking; Field-based activity model; Piperazine; hAChE.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholinesterase / metabolism
  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / enzymology
  • Cholinesterase Inhibitors / chemical synthesis*
  • Cholinesterase Inhibitors / pharmacology*
  • Coumarins / chemical synthesis*
  • Coumarins / pharmacology*
  • Drug Design*
  • GPI-Linked Proteins / antagonists & inhibitors
  • GPI-Linked Proteins / metabolism
  • Humans
  • Hydrophobic and Hydrophilic Interactions
  • Molecular Docking Simulation*
  • Piperazines / chemical synthesis*
  • Piperazines / pharmacology*
  • Quantitative Structure-Activity Relationship

Substances

  • Cholinesterase Inhibitors
  • Coumarins
  • GPI-Linked Proteins
  • Piperazines
  • ACHE protein, human
  • Acetylcholinesterase